Charles A. Mack
Research Subjects
Charles A. Mack has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Berhane Worku
Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA -
4 shared publications Bhupinder Singh
3 shared publicationsStacey Ruiz
3 shared publicationsAndre Lamy
2 shared publicationsChao Wang
2 shared publicationsFederico Milla
Department of Cardiothoracic Surgery
2 shared publications
Latest Publications
- Open Access
- 24 January 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (2)
Human fibrinogen concentrate Fibryga® enables rapid reversal of thrombolysis and timely repair of acute Stanford type A aortic dissection: a case report
Background: Acute Stanford type A aortic dissection (ATAAD) may mimic acute ischaemic stroke (AIS), occasionally resulting in administration of thrombolytics and potentially leading to life-threatening haemorrhage. Rapid recognition and reversal of thrombolysis-associated coagulopathy are essential to permit timely surgery. Case summary: A 53-year-old man with history of poorly controlled hypertension presented with acute right-sided hemiparesis, aphasia, and dysarthria. AIS was suspected, and intravenous tenecteplase (TNK) was administered once intracranial haemorrhage was ruled out on non-contrast head computerized tomography (CT) scan. Shortly after thrombolysis, CT angiogram revealed an ATAAD with occlusion of the left common carotid artery, significant compression of true lumen, and involvement of both femoral arteries. TNK was immediately reversed with cryoprecipitate and human fibrinogen concentrate (Fibryga®), raising fibrinogen level within an hour from 102 to 234 mg/dL, thereby enabling timely emergent repair of acute type A dissection. Despite a complicated intra- and post-operative course that included cardiac arrest secondary to rupture and haemopericardium, acute kidney injury, and bowel perforation, the patient was discharged to rehabilitation facility with favourable neurological function. Discussion: This case illustrates the diagnostic pitfall of ATAAD presenting as stroke and highlights the utility and safety of fibrinogen concentrate (Fibryga®) in rapid reversal of thrombolysis-associated coagulopathy, allowing for safe and timely surgical intervention for ATAAD.
- 24 January 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (2)
Open AccessHuman fibrinogen concentrate Fibryga® enables rapid reversal of thrombolysis and timely repair of acute Stanford type A aortic dissection: a case report
Background: Acute Stanford type A aortic dissection (ATAAD) may mimic acute ischaemic stroke (AIS), occasionally resulting in administration of thrombolytics and potentially leading to life-threatening haemorrhage. Rapid recognition and reversal of thrombolysis-associated coagulopathy are essential to permit timely surgery. Case summary: A 53-year-old man with history of poorly controlled hypertension presented with acute right-sided hemiparesis, aphasia, and dysarthria. AIS was suspected, and intravenous tenecteplase (TNK) was administered once intracranial haemorrhage was ruled out on non-contrast head computerized tomography (CT) scan. Shortly after thrombolysis, CT angiogram revealed an ATAAD with occlusion of the left common carotid artery, significant compression of true lumen, and involvement of both femoral arteries. TNK was immediately reversed with cryoprecipitate and human fibrinogen concentrate (Fibryga®), raising fibrinogen level within an hour from 102 to 234 mg/dL, thereby enabling timely emergent repair of acute type A dissection. Despite a complicated intra- and post-operative course that included cardiac arrest secondary to rupture and haemopericardium, acute kidney injury, and bowel perforation, the patient was discharged to rehabilitation facility with favourable neurological function. Discussion: This case illustrates the diagnostic pitfall of ATAAD presenting as stroke and highlights the utility and safety of fibrinogen concentrate (Fibryga®) in rapid reversal of thrombolysis-associated coagulopathy, allowing for safe and timely surgical intervention for ATAAD.
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 2025 (1)
Effects of RBT‐1 on the Occurrence of Postoperative Complications in Patients Undergoing Cardiac Surgery
Objectives: Approximately two‐thirds of patients undergoing cardiac surgery experience postoperative complications, which may lead to significant clinical consequences. RBT‐1, an investigational drug with anti‐inflammatory and antioxidant properties, elicits a preconditioning response and was shown to improve clinical outcomes when administered within 24–48 hours prior to surgery (modified intention‐to‐treat population). The current post hoc analysis evaluated the efficacy of RBT‐1 in reducing postoperative complications in the entire study population without excluding patients based on when surgery occurred relative to study drug administration. Methods: A total of 135 patients were randomized to receive a single infusion of RBT‐1 ( n = 91) or placebo ( n = 44) at least 1 day before undergoing nonemergent coronary artery bypass graft (CABG) and/or heart valve surgery on cardiopulmonary bypass (CPB) and were followed for 90 days postsurgery. Clinical outcomes assessed included ventilator time, intensive care unit (ICU) and hospital length of stay (LOS), cardiopulmonary readmission, and other clinical events of interest. Results: In this analysis, RBT‐1 reduced ventilator time, ICU, and hospital LOS by 0.98 days (NS), 2.59 days ( p = 0.026), and 1.35 days (NS), respectively, compared with placebo. The incidence of 30‐day cardiopulmonary readmission was significantly reduced by RBT‐1 (4.6% vs. 17.5%, placebo; p = 0.035). Additionally, RBT‐1 showed a trend in reductions in several clinical events of interest, including anemia, atrial fibrillation, and fluid overload. Conclusions: Trends in improved clinical outcomes were seen with RBT‐1 treatment in this post hoc analysis that included all patients enrolled in a Phase 2 clinical study regardless of surgery delay beyond 2 days posttreatment. A Phase 3 study is underway to confirm these improved clinical outcomes in a larger study population. Trial Registration: ClinicalTrials.gov identifier: NCT06021457
- 1 January 2025
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 2025 (1)
Open AccessEffects of RBT‐1 on the Occurrence of Postoperative Complications in Patients Undergoing Cardiac Surgery
Objectives: Approximately two‐thirds of patients undergoing cardiac surgery experience postoperative complications, which may lead to significant clinical consequences. RBT‐1, an investigational drug with anti‐inflammatory and antioxidant properties, elicits a preconditioning response and was shown to improve clinical outcomes when administered within 24–48 hours prior to surgery (modified intention‐to‐treat population). The current post hoc analysis evaluated the efficacy of RBT‐1 in reducing postoperative complications in the entire study population without excluding patients based on when surgery occurred relative to study drug administration. Methods: A total of 135 patients were randomized to receive a single infusion of RBT‐1 ( n = 91) or placebo ( n = 44) at least 1 day before undergoing nonemergent coronary artery bypass graft (CABG) and/or heart valve surgery on cardiopulmonary bypass (CPB) and were followed for 90 days postsurgery. Clinical outcomes assessed included ventilator time, intensive care unit (ICU) and hospital length of stay (LOS), cardiopulmonary readmission, and other clinical events of interest. Results: In this analysis, RBT‐1 reduced ventilator time, ICU, and hospital LOS by 0.98 days (NS), 2.59 days ( p = 0.026), and 1.35 days (NS), respectively, compared with placebo. The incidence of 30‐day cardiopulmonary readmission was significantly reduced by RBT‐1 (4.6% vs. 17.5%, placebo; p = 0.035). Additionally, RBT‐1 showed a trend in reductions in several clinical events of interest, including anemia, atrial fibrillation, and fluid overload. Conclusions: Trends in improved clinical outcomes were seen with RBT‐1 treatment in this post hoc analysis that included all patients enrolled in a Phase 2 clinical study regardless of surgery delay beyond 2 days posttreatment. A Phase 3 study is underway to confirm these improved clinical outcomes in a larger study population. Trial Registration: ClinicalTrials.gov identifier: NCT06021457
- Open Access
- 1 July 2024
- Published by Elsevier in JTCVS Open
- Vol. 22, 61-64
RBT-1 reduces blood product utilization in patients undergoing nonemergency coronary artery bypass grafting and/or valve surgery
- 1 July 2024
- Published by Elsevier in JTCVS Open
- Vol. 22, 61-64
Open AccessRBT-1 reduces blood product utilization in patients undergoing nonemergency coronary artery bypass grafting and/or valve surgery
- Open Access
- 8 January 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 68, 102364
Effects of RBT-1 on preconditioning response biomarkers in patients undergoing coronary artery bypass graft or heart valve surgery: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
- 8 January 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 68, 102364
Open AccessEffects of RBT-1 on preconditioning response biomarkers in patients undergoing coronary artery bypass graft or heart valve surgery: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
- Open Access
- 29 June 2023
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 2 (5)
Feasibility and Safety of Impella-Assisted High-Risk PCI Before TAVR in Patients With Severe Aortic Stenosis
- 29 June 2023
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 2 (5)
Open AccessFeasibility and Safety of Impella-Assisted High-Risk PCI Before TAVR in Patients With Severe Aortic Stenosis
- Open Access
- 3 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (5) , 2022
Angiographic Outcomes for Arterial and Venous Conduits Used in CABG
Coronary artery bypass grafting is the most commonly performed cardiac surgical procedure. Conduit selection is crucial to achieving early optimal outcomes, with graft patency being likely the main driver to long-term survival. We present a review of current evidence on the patency of arterial and venous bypass conduits and of differences in angiographic outcomes.
- 3 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (5) , 2022
Open AccessAngiographic Outcomes for Arterial and Venous Conduits Used in CABG
Coronary artery bypass grafting is the most commonly performed cardiac surgical procedure. Conduit selection is crucial to achieving early optimal outcomes, with graft patency being likely the main driver to long-term survival. We present a review of current evidence on the patency of arterial and venous bypass conduits and of differences in angiographic outcomes.
- 29 June 2022
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 37 (9) , 2732-2733
Embolization during cardiac surgery; to prevent or intercept
- 29 June 2022
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 37 (9) , 2732-2733
Embolization during cardiac surgery; to prevent or intercept
- Open Access
- 31 May 2022
- Published by Georg Thieme Verlag KG in AORTA
- Vol. 10 (01) , 032-034
Blunt Traumatic Innominate Artery Pseudoaneurysm Endografting without Heparin Due to Severe Brain Injury
Blunt traumatic innominate artery injuries occur in polytrauma victims who have suffered high-speed motor vehicle collisions. Their associated injuries may preclude the use of heparin and affect surgical management and perioperative neurological risk. The uniqueness of this case is combining the arterial injury repair with a severe progressive neurological injury that prohibited standard perioperative antiplatelet or anticoagulent use.
- 31 May 2022
- Published by Georg Thieme Verlag KG in AORTA
- Vol. 10 (01) , 032-034
Open AccessBlunt Traumatic Innominate Artery Pseudoaneurysm Endografting without Heparin Due to Severe Brain Injury
Blunt traumatic innominate artery injuries occur in polytrauma victims who have suffered high-speed motor vehicle collisions. Their associated injuries may preclude the use of heparin and affect surgical management and perioperative neurological risk. The uniqueness of this case is combining the arterial injury repair with a severe progressive neurological injury that prohibited standard perioperative antiplatelet or anticoagulent use.
- 1 April 2022
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 113 (4) , 1112-1118
Implementing a High-Value Care Discharge Protocol in Patients Undergoing CABG Reduces Readmission
- 1 April 2022
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 113 (4) , 1112-1118
Implementing a High-Value Care Discharge Protocol in Patients Undergoing CABG Reduces Readmission